DICE Therapeutics (DICE) Stock Price, News & Analysis

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DICE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DICE, but not buy additional shares or sell existing shares.
View DICE analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 12 month price objectives for DICE Therapeutics' stock. Their DICE share price targets range from $48.00 to $71.00. On average, they anticipate the company's share price to reach $55.67 in the next year. This suggests a possible upside of 17.1% from the stock's current price.
View analysts price targets for DICE or view top-rated stocks among Wall Street analysts.

DICE Therapeutics, Inc. (NASDAQ:DICE) posted its quarterly earnings results on Friday, November, 12th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($0.53) by $1.77.

Principal Healthcare Innovators ETF holds 6,865 shares of DICE stock, representing 0.61% of its portfolio.

DICE Therapeutics (DICE) raised $160 million in an IPO on Wednesday, September 15th 2021. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share.